EFFECT OF COVID-19 DISEASE IN SMELL AND TASTE OF PATIENTS WITH MILD, MODERATE OR SEVERE SYMPTOMATOLOGY
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Eligible participants who will be recruited in this research protocol will be adult patients who are diagnosed positive for SARS-COV2, infection with Real Time Polymerase Chain Reaction Test (RT-PCR).
The study population will be divided in two groups. The first group will be consisted with positive patients that were referred to either the Emergency Department (ED) of Infectious Diseases or at the Outpatient Clinic screening for SARS-COV2 and are being self-quarantined at home. The participants will be hospitalized patients in the Infectious Diseases Unit (IDU) of the University General Hospital of Ioannina.
The examination will be performed at the moment of diagnosis both for self-quarantine patients and for in hospitalized patients. The follow up evaluation will be a re-examination, performed at least four weeks after the moment of diagnosis. The time internal of reassessing the patients chosen according to current literature, estimated that is the minimum reassessment interval and seems to be a reference time for either progression stabilization or recession of the symptoms of anosmia/ ageusia (12, 13).
Patients will be asked to evaluate their olfactory and gustatory abilities through the visual analogue scale (VAS), at three time points: 1.before infection( as they can recall it), 2. at the time of diagnosis and 3. four weeks later(14).
Patients' scoring will be recorded in a horizontal presentation of 100 VAS points, where zero refers to no smell or taste while 100 refers to normal sensation. In addition, patients will rate their nasal obstruction and rhinorrhea on a similar VAS scale, where 0 refers to a completely blocked nose and an excessively runny nose while 100 indicates normal nasal breathing and a no runny nose. All patients will assess the intensity of the olfactory and taste function, through a self testing them at home. Patients will rate from 0 to 100 the intensity of smell, after being exposed to five common household odors (ie lemon juice, oregano, instant coffee, toothpaste and mint gum).The choice of these substances is based on their influence at the irritation of the trigeminal nerve.
The intensity of taste function will be evaluated using four(4) substances: sugar, salt, lemon juice and instant coffee (decaffeinated), that represent the following 4 basic quality flavors:sweet, salty, sour and bitter. Every patient will have to receive orally half a teaspoon of each testant and report the quality of taste perception. After each testant they have to rinse their mouth with tap water. Bitter testant will have to be tested in the end.
Patient demographics, associated symptoms, and comorbidities will be recorded. The patients will have to report and fill in symptoms such as fever, cough, shortness of breath or dyspnea, fatigue, muscle aches, runny nose, blocked nose, loss of smell, and loss of taste.
The results will be recorded in a questionnaire.
Covid-19 positive patients recovering at home, will be informed for the study either by telephone or in person, following all the safety measures provided by National Organization of Public Health of Greece, by one of the investigators officially participating in the study. A questionnaire will be completed by the examinee, after telephone information about the purpose of the study and after providing a written consent from.
In hospitalized patients in the Infectious Diseases Unit, will be informed by the investigators participating in the study and will follow the above procedure.
This study was submitted for approval to the research ethic committee and the scientific council of University General Hospital of Ioannina and was accepted.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Epirus
-
Ioannina, Epirus, Greece, 45500
- University General Hospital of Ioannina
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
adult>18 years old
- COVID-19 positive patient, via RT-PCR test
- Patient referred to the University General Hospital of Ioannina
Exclusion Criteria:
Age <18
- Previous nasal surgery, endoscopic sinus surgery
- Head and neck radiotherapy
- Head injury
- Allergic rhinitis
- Chronis Rhinosinusitis
- Psychiatric/ Neurological disorders
- Disorders that altering the level of consciousness (Glasgow Coma Scale <15)
- History of smell and taste disorder
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
home-quarantined patients
|
A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
|
|
inhospitalized patients
|
A visual analog scale (VAS) is a measurement device used to quantify a subjective experience.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
oflactory and taste dysfunction in SARS-CoV2 infection
Time Frame: 4 WEEKS
|
4 WEEKS
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: CHARALAMPOS MILIONIS, PROFESSOR, University General Hospital of Ioannina
- Principal Investigator: IOANNIS KASTANIOUDAKIS, PROFESSOR, University General Hospital of Ioannina
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Neurologic Manifestations
- Sensation Disorders
- COVID-19
- Taste Disorders
Other Study ID Numbers
Other Study ID Numbers
- 931/17-11-2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Olfactory and Taste Dysfunction in SARS-CoV2 Infection
-
NCT04410432CompletedSARS Cov2, Immune Response
-
NCT05162456RecruitingSARS-CoV2 Infection | SARS-CoV2 Antibodies
-
NCT04937712RecruitingSARS-CoV2 Infection | Proximal Tubule Dysfunction
-
NCT04371692Completed
-
NCT05109585Active, not recruitingSARS-CoV2 Infection | SARS-CoV2 Antibodies
-
NCT06456008RecruitingTaste Disorders | Olfactory Disorder | Smell Disorder | Smell Dysfunction
-
NCT04816760UnknownEndothelial Dysfunction | Sars-CoV2 | Immunization; Infection | Innate Immunity | Alveolar Lung Disease
-
NCT04401163CompletedCovid19 | Sars-CoV2
-
NCT04362267Withdrawn
-
NCT04726137CompletedSars-Cov2 Antibodies in Children and Adolescents Living With HIV
Clinical Trials on visual analogue scale
-
NCT04770857Not yet recruitingPost-ERCP Acute Pancreatitis
-
NCT06017466Not yet recruiting
-
NCT04139590CompletedPostoperative Pain
-
NCT04231955Completed
-
NCT05226208Completed
-
NCT07500792Not yet recruiting
-
NCT02137135CompletedAcute Postoperative Pain | Chronic Postoperative Pain
-
NCT06475079Not yet recruiting